1
|
Carrasco Colom J, Manzanares Á, Álvaro Gómez A, Serrano Escribano I, Esquivel E, Pérez-Rivilla A, Moral-Pumarega MT, Aguirre Pascual E, De Vergas J, Reda Del Barrio S, Moraleda C, Epalza C, Fernández-Cooke E, Prieto L, Villaverde S, Zamora B, Herraiz I, Galindo A, Folgueira MD, Delgado R, Blázquez-Gamero D. Clinical outcomes and antibody transfer in a cohort of infants with in utero or perinatal exposure to SARS-CoV-2 (Coronascope Study). Eur J Pediatr 2023; 182:4647-4654. [PMID: 37561198 DOI: 10.1007/s00431-023-05147-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 07/27/2023] [Accepted: 08/01/2023] [Indexed: 08/11/2023]
Abstract
We aimed to describe the outcomes, focusing on the hearing and neurological development, of infants born to mothers with COVID-19 during pregnancy and to evaluate the persistence of maternal antibodies in the first months of life. An observational, prospective study at a tertiary hospital in Madrid (Spain) on infants born to mothers with COVID-19 during pregnancy between March and September 2020 was conducted. A follow-up visit at 1-3 months of age with a physical and neurological examination, cranial ultrasound (cUS), SARS-CoV-2 RT-PCR on nasopharyngeal swab, and SARS-CoV-2 serology were performed. Hearing was evaluated at birth through the automated auditory brainstem response and at six months of age through the auditory steady-state response. A neurodevelopmental examination using the Bayley-III scale was performed at 12 months of age. Of 95 infants studied, neurological examination was normal in all of them at the follow-up visit, as was the cUS in 81/85 (95%) infants, with only mild abnormalities in four of them. Serology was positive in 47/95 (50%) infants, which was not associated with symptoms or severity of maternal infection. No hearing loss was detected, and neurodevelopment was normal in 96% of the infants (median Z score: 0). CONCLUSION In this cohort, the majority of infants born to mothers with COVID-19 during pregnancy were healthy infants with a normal cUS, no hearing loss, and normal neurodevelopment in the first year of life. Only half of the infants had a positive serological result during the follow-up. WHAT IS KNOWN • Hearing loss and neurodevelopmental delay in infants born to mothers with COVID-19 during pregnancy has been suggested, although data is inconsistent. Maternal antibody transfer seems to be high, with a rapid decrease during the first weeks of life. WHAT IS NEW • Most infants born to mothers with COVID-19 during pregnancy had normal hearing screening, cranial ultrasound, and neurodevelopmental status at 12 months of life. Antibodies against SARS-CoV-2 were only detected in 50% of the infants at two months of life.
Collapse
Affiliation(s)
- Jaime Carrasco Colom
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Ángela Manzanares
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain.
| | | | | | - Estrella Esquivel
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Alfredo Pérez-Rivilla
- Microbiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Maria Teresa Moral-Pumarega
- Neonatology Department, Hospital Universitario 12 de Octubre, RICORS Network, ISCIII, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | | | - Joaquín De Vergas
- Pediatric Otorhinolaryngology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Sara Reda Del Barrio
- Pediatric Otorhinolaryngology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Cinta Moraleda
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Cristina Epalza
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Elisa Fernández-Cooke
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Luis Prieto
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
- Universidad Complutense de Madrid, Madrid, Spain
| | - Serena Villaverde
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
| | - Berta Zamora
- Neuropsychology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Ignacio Herraiz
- Universidad Complutense de Madrid, Madrid, Spain
- Fetal Medicine Unit, Obstetrics and Gynecology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
- Primary Care Interventions to Prevent Chronic Maternal and Child Diseases of Perinatal and Developmental Origin (RICORS Network), Instituto de Salud Carlos III, RD21/0012/0024, Madrid, Spain
| | - Alberto Galindo
- Universidad Complutense de Madrid, Madrid, Spain
- Fetal Medicine Unit, Obstetrics and Gynecology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
- Primary Care Interventions to Prevent Chronic Maternal and Child Diseases of Perinatal and Developmental Origin (RICORS Network), Instituto de Salud Carlos III, RD21/0012/0024, Madrid, Spain
| | - María Dolores Folgueira
- Microbiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Rafael Delgado
- Microbiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Daniel Blázquez-Gamero
- Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
- Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Hospital, RECLIP, 12 de Octubre (imas12), Madrid, Spain
- Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
2
|
Gómez-Montes E, Salcedo Lobato E, Galindo A, García Alcázar D, Villalain C, Moral-Pumarega MT, Bustos Lozano G, Luna-Paredes C. Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: A promising way to change the impact of cystic fibrosis. Fetal Diagn Ther 2023:000530261. [PMID: 36996799 DOI: 10.1159/000530261] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Accepted: 03/16/2023] [Indexed: 04/01/2023]
Abstract
INTRODUCTION Cystic fibrosis (CF) is a potentially severe disease. The development of new therapies with cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been a great advance in the management of this condition because they improve the function of the faulty CFTR protein rather than palliate its consequences. CFTR modulator therapy improves pancreatic and lung function and, therefore, quality of life, with greater benefits the sooner treatment is started. For this reason, the use of these therapies is being approved for increasingly younger patients. Only two cases of pregnant women taking CFTR modulators therapy with CF fetuses have been reported, suggesting that it could resolve meconium ileus (MI) prenatally, and delay/prevent other consequences of CF. CASE PRESENTATION We report a case of a healthy pregnant patient who underwent CFTR modulator therapy with elexacaftor-tezacaftor-ivacaftor (ETI) in order to treat her fetus with CF (F508del homozygous CFTR mutation) and MI. Ultrasound findings suggestive of MI were observed at 24 weeks. Both parents were tested for CFTR mutations, and both were carriers of the F508del CFTR mutation. The fetus was diagnosed with CF by amniocentesis at 26+2 weeks. Maternal ETI therapy was initiated at 31+1 weeks and no dilated bowel was observed at 39 weeks. There were no signs of bowel obstruction after birth. Maternal ETI treatment was continued during breastfeeding, with normal liver function. Immunoreactive trypsinogen in the newborn was 58.1 ng/mL, sweat chloride test was 80 mmol/l, and fecal elastase on the second day of life was 58 μg/g. DISCUSSION/CONCLUSION Prenatal ETI treatment, as well as during breastfeeding, could solve, prevent and/or delay CF complications.
Collapse
|
3
|
Jiménez-Lozano I, Caro-Teller JM, Fernández-Hidalgo N, Miarons M, Frick MA, Batllori Badia E, Serrano B, Parramon-Teixidó CJ, Camba-Longueira F, Moral-Pumarega MT, San Juan-Garrido R, Cabañas Poy MJ, Suy A, Gorgas Torner MQ. Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study. J Clin Pharm Ther 2021; 46:1062-1070. [PMID: 33638257 PMCID: PMC8014796 DOI: 10.1111/jcpt.13394] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 02/09/2021] [Accepted: 02/10/2021] [Indexed: 12/20/2022]
Abstract
What is known and objective Tocilizumab is an IL‐6 receptor inhibitor agent which has been proposed as a candidate to stop the inflammatory phase of infection by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). However, safety data of tocilizumab in pregnant women and their newborn are scarce. We aimed to describe maternal and neonatal safety outcomes associated with tocilizumab treatment in pregnant women with severe COVID‐19. Methods This is a retrospective study of severe COVID‐19 pregnant women, treated with tocilizumab in two Spanish hospitals between 1 March and 31 April 2020. Demographics, medical history, clinical and radiologic findings, treatment information and laboratory data of mothers and their newborns were collected from electronic medical records. Results and discussion A total of 12 pregnant women were identified to have received tocilizumab during pregnancy in the two hospitals. Median gestational age at admission was 27.7 weeks (interquartile range, 18.0–36.4). Most of them received lopinavir/ritonavir, azithromycin and hydroxychloroquine, two patients received corticosteroids and one received interferon beta 1B. All 12 pregnancies resulted in live births. Somatometric values were normal for all newborns, and evolution at 14 and 28 days was favourable for all of them. Hepatotoxicity was observed in 2 patients, which improved or resolved at discharge. Cytomegalovirus reactivation was detected in another patient who had also received corticosteroids for 15 days, causing a congenital infection in her newborn. Both hepatotoxicity and viral reactivation adverse events were classified as possibly related to tocilizumab administration according to Naranjo's causality algorithm. What is new and conclusions It does not appear that tocilizumab has detrimental effects for the mother and newborn. Close monitoring of infections should be considered, especially if other immunosuppressive agents are used.
Collapse
Affiliation(s)
- Inés Jiménez-Lozano
- Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - José Manuel Caro-Teller
- Pharmacy Department. Hospital, Universitario "12 de Octubre", Research Institute 12 de Octubre (i+12, Madrid, Spain
| | - Nuria Fernández-Hidalgo
- Pediatric Infectious Diseases and Primary Immunodeficiencies Unit, Pediatrics Department, Vall d´hebron Hospital, Barcelona, Spain
| | - Marta Miarons
- Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Marie Antoinette Frick
- Pediatric Infectious Diseases and Primary Immunodeficiencies Unit, Pediatrics Department, Vall d´hebron Hospital, Barcelona, Spain
| | - Emma Batllori Badia
- Unit of perinatal medicine, Obstetric and Gynaecology Department, Hospital Universitario "12 de Octubre", Research Institute 12 de Octubre (i+12, Madrid, Spain
| | - Berta Serrano
- Department of Obstetrics and Gynecology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | | | - Fátima Camba-Longueira
- Department of Neonatology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Maria Teresa Moral-Pumarega
- Unit of perinatal medicine, Obstetric and Gynaecology Department, Hospital Universitario "12 de Octubre", Research Institute 12 de Octubre (i+12, Madrid, Spain
| | - Rafael San Juan-Garrido
- Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Research Institute 12 de Octubre (i+12, Madrid, Spain
| | - Maria Josep Cabañas Poy
- Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Anna Suy
- Department of Obstetrics and Gynecology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Maria Queralt Gorgas Torner
- Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| |
Collapse
|
4
|
Nuñez-Ramiro A, Benavente-Fernández I, Valverde E, Cordeiro M, Blanco D, Boix H, Cabañas F, Chaffanel M, Fernández-Colomer B, Fernández-Lorenzo JR, Kuligowski J, Loureiro B, Moral-Pumarega MT, Pavón A, Sánchez-Illana A, Tofé I, Hervás D, García-Robles A, Parra-Llorca A, Cernada M, Martinez-Rodilla J, Lorente-Pozo S, Llorens R, Marqués R, Vento M. Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial. Neonatology 2019; 116:76-84. [PMID: 31091527 DOI: 10.1159/000499084] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 02/22/2019] [Indexed: 11/19/2022]
Abstract
BACKGROUND AND OBJECTIVES Therapeutic interventions to improve the efficacy of whole-body cooling for hypoxic-ischemic encephalopathy (HIE) are desirable. Topiramate has been effective in reducing brain damage in experimental studies. However, in the clinical setting information is limited to a small number of feasibility trials. We launched a randomized controlled double-blinded topiramate/placebo multicenter trial with the primary objective being to reduce the antiepileptic activity in cooled neonates with HIE and assess if brain damage would be reduced as a consequence. STUDY DESIGN Neonates were randomly assigned to topiramate or placebo at the initiation of hypothermia. Topiramate was administered via a nasogastric tube. Brain electric activity was continuously monitored. Topiramate pharmacokinetics, energy-related and Krebs' cycle intermediates, and lipid peroxidation biomarkers were determined using liquid chromatography-mass spectrometry and MRI for assessing brain damage. RESULTS Out of 180 eligible patients 110 were randomized, 57 (51.8%) to topiramate and 53 (48.2%) to placebo. No differences in the perinatal or postnatal variables were found. The topiramate group exhibited less seizure burden in the first 24 h of hypothermia (topiramate, n = 14 [25.9%] vs. placebo, n = 22 [42%]); needed less additional medication, and had lower mortality (topiramate, n = 5 [9.2%] vs. placebo, n = 10 [19.2%]); however, these results did not achieve statistical significance. Topiramate achieved a therapeutic range in 37.5 and 75.5% of the patients at 24 and 48 h, respectively. A significant association between serum topiramate levels and seizure activity (p < 0.016) was established. No differences for oxidative stress, energy-related metabolites, or MRI were found. CONCLUSIONS Topiramate reduced seizures in patients achieving therapeutic levels in the first hours after treatment initiation; however, they represented only a part of the study population. Our results warrant further studies with higher loading and maintenance dosing of topiramate.
Collapse
Affiliation(s)
- Antonio Nuñez-Ramiro
- Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain
| | | | - Eva Valverde
- Division of Neonatology, University Hospital La Paz, Madrid, Spain
| | - Malaika Cordeiro
- Division of Neonatology, University Hospital La Paz, Madrid, Spain
| | - Dorotea Blanco
- Division of Neonatology, University Hospital Gregorio Marañón, Madrid, Spain
| | - Hector Boix
- Department of Neonatology, University Hospital Vall d'Hebrón, Barcelona, Spain
| | - Fernando Cabañas
- Division of Neonatology, University Hospital Quirónsalud Madrid, Madrid, Spain
| | - Mercedes Chaffanel
- Division of Neonatology, Regional University Hospital Málaga, Málaga, Spain
| | | | | | | | - Begoña Loureiro
- Division of Neonatology, University Hospital Cruces, Bilbao, Spain
| | | | - Antonio Pavón
- Division of Neonatology, University Hospital Virgen del Rocío, Sevilla, Spain
| | | | - Inés Tofé
- Division of Neonatology, University Hospital Reina Sofía, Córdoba, Spain
| | - David Hervás
- Department of Biostatistics, Health Research Institute La Fe, Valencia, Spain
| | - Ana García-Robles
- Division of Neonatology, University Hospital Complex of Vigo, Vigo, Spain
| | - Anna Parra-Llorca
- Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain
| | - Maria Cernada
- Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain
| | | | | | - Roberto Llorens
- Department of Radiology, University and Polytechnic Hospital La Fe, Valencia, Spain
| | - Remedios Marqués
- Departament of Pharmacy, University and Polytechnic Hospital La Fe, Valencia, Spain
| | - Máximo Vento
- Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain, .,Health Research Institute La Fe, Valencia, Spain,
| | | |
Collapse
|
5
|
Sánchez-Illana Á, Núñez-Ramiro A, Cernada M, Parra-Llorca A, Valverde E, Blanco D, Moral-Pumarega MT, Cabañas F, Boix H, Pavon A, Chaffanel M, Benavente-Fernández I, Tofe I, Loureiro B, Fernández-Lorenzo JR, Fernández-Colomer B, García-Robles A, Kuligowski J, Vento M. Evolution of Energy Related Metabolites in Plasma from Newborns with Hypoxic-Ischemic Encephalopathy during Hypothermia Treatment. Sci Rep 2017; 7:17039. [PMID: 29213095 PMCID: PMC5719006 DOI: 10.1038/s41598-017-17202-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 11/22/2017] [Indexed: 12/17/2022] Open
Abstract
Therapeutic hypothermia (TH) initiated within 6 h from birth is the most effective therapeutic approach for moderate to severe hypoxic-ischemic encephalopathy (HIE). However, underlying mechanisms and effects on the human metabolism are not yet fully understood. This work aims at studying the evolution of several energy related key metabolites in newborns with HIE undergoing TH employing gas chromatography - mass spectrometry. The method was validated following stringent FDA requirements and applied to 194 samples from a subgroup of newborns with HIE (N = 61) enrolled in a multicenter clinical trial (HYPOTOP) for the determination of lactate, pyruvate, ketone bodies and several Krebs cycle metabolites at different sampling time points. The analysis of plasma samples from newborns with HIE revealed a decrease of lactate, pyruvate and β-hydroxybutyrate concentrations, whereas rising malate concentrations were observed. In healthy control newborns (N = 19) significantly lower levels of pyruvate and lactate were found in comparison to age-matched newborns with HIE undergoing TH, whereas acetoacetate and β-hydroxybutyrate levels were clearly increased. Access to a validated analytical method and a controlled cohort of newborns with HIE undergoing hypothermia treatment for the first time allowed the in-depth study of the evolution of key metabolites of metabolic junctions in this special population.
Collapse
Affiliation(s)
- Ángel Sánchez-Illana
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - Antonio Núñez-Ramiro
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - María Cernada
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - Anna Parra-Llorca
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - Eva Valverde
- Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain
| | - Dorotea Blanco
- Hospital Universitario Gregorio Marañón, C/O'Donnell 48-50, 28009, Madrid, Spain
| | | | - Fernando Cabañas
- Hospital Universitario Quirónsalud Madrid, Calle Diego de Velazquez s/n, 28223, Madrid, Spain
| | - Hector Boix
- Hospital Universitario Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Antonio Pavon
- Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot, s/n, 41013, Sevilla, Spain
| | - Mercedes Chaffanel
- Hospital Materno Infantil Carlos Haya, Avda. Arroyo de los Angeles s/n, 29011, Málaga, Spain
| | | | - Inés Tofe
- Hospital Universitario Reina Sofía, Avda. Menendez Pidal s/n, 14004, Córdoba, Spain
| | - Begoña Loureiro
- Hospital Universitario Cruces, Plaza Cruces s/n, 48903, Barakaldo, Vizcaya, Spain
| | | | | | - Ana García-Robles
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain
| | - Julia Kuligowski
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain.
| | - Máximo Vento
- Neonatal Research Unit, Health Research Institute La Fe, Valencia, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain.
- Division of Neonatology, University & Polytechnic Hospital La Fe, Avda. Fernando Abril Martorell 106, 46026, Valencia, Spain.
| |
Collapse
|
6
|
Pallás-Alonso C, Rodriguez-López J, Moral-Pumarega MT. Degree of Compliance with a Protocol for Performing Safe Skin-to-Skin Care. J Hum Lact 2016; 32:183. [PMID: 26744500 DOI: 10.1177/0890334415616614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
de Alba-Romero C, Camaño-Gutiérrez I, López-Hernández P, de Castro-Fernández J, Barbero-Casado P, Salcedo-Vázquez ML, Sánchez-López D, Cantero-Arribas P, Moral-Pumarega MT, Pallás-Alonso CR. Postcesarean Section Skin-to-Skin Contact of Mother and Child. J Hum Lact 2014; 30:283-286. [PMID: 24847031 DOI: 10.1177/0890334414535506] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The first hour postpartum is critical for long-term, healthy development. At 12 de Octubre Hospital, Madrid, Spain, we developed and implemented a multidisciplinary strategy based on a consensual, participatory protocol for all health care professionals involved in cesarean deliveries. Our aims were 2-fold: the initiation of skin-to-skin (StS) contact with the newborn immediately after birth, regardless of the feeding method chosen, and the recognition of the importance of a companion present for support during the cesarean section (father or other designated by the mother). The objective of this article is to describe a policy developed to ensure timely postcesarean StS contact. Our protocol for neonatal StS contact with the mother is based on reported benefits found in literature, the World Health Organization's international recommendations, and deep respect for a process that is both natural and instinctive. We call it "humanizing the cesarean."
Collapse
Affiliation(s)
| | - Isabel Camaño-Gutiérrez
- Department of Obstetrics and Gynecology, 12 de Octubre University Hospital (SERMAS), Madrid, Spain
| | - Paloma López-Hernández
- Department of Obstetrics and Gynecology, 12 de Octubre University Hospital (SERMAS), Madrid, Spain
| | | | - Patricia Barbero-Casado
- Department of Obstetrics and Gynecology, 12 de Octubre University Hospital (SERMAS), Madrid, Spain
| | | | - Dolores Sánchez-López
- Department of Neonatology, 12 de Octubre University Hospital (SERMAS), Madrid, Spain
| | - Pilar Cantero-Arribas
- Department of Neonatology, 12 de Octubre University Hospital (SERMAS), Madrid, Spain
| | | | | |
Collapse
|